What are the differences between ceftazidime‑avibactam, ceftolozane‑tazobactam, and the combination of ceftazidime‑avibactam with aztreonam?

Key Differences Between Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam Plus Aztreonam

The critical distinction lies in the carbapenemase type: use ceftazidime-avibactam or ceftolozane-tazobactam for KPC and OXA-48 producers, but add aztreonam to ceftazidime-avibactam specifically for metallo-β-lactamase (MBL) producers like NDM.

Spectrum of Activity

Ceftazidime-Avibactam (CAZ-AVI)

• Optimal for: KPC-producing and OXA-48-producing carbapenem-resistant Enterobacterales (CRE), with nearly 100% susceptibility 1
• Active against: Multidrug-resistant Pseudomonas aeruginosa (though insufficient evidence compared to ceftolozane-tazobactam) 2
• Critical limitation: NOT active against MBL-producing organisms when used alone 1
• Demonstrates reduced mortality (RR 0.49,95% CI 0.34-0.70) and treatment failure compared to older agents for CRE 1

Ceftolozane-Tazobactam (C-T)

• Optimal for: Difficult-to-treat carbapenem-resistant Pseudomonas aeruginosa (CRPA) 2
• Advantage over CAZ-AVI: Lower risk of recurrent infection within 30-90 days (aOR 0.46,95% CI 0.26-0.78) for drug-resistant P. aeruginosa 3
• Comparable efficacy: Similar mortality, clinical response, and resistance emergence rates to CAZ-AVI for MDR Pseudomonas 3, 4
• Limitation: Less effective than CAZ-AVI for Enterobacterales, particularly CRE

Ceftazidime-Avibactam PLUS Aztreonam (CAZ-AVI + ATM)

• Specifically indicated for: MBL-producing CRE (NDM, VIM producers) 1
• Mechanism: Aztreonam is not hydrolyzed by metallo-β-lactamases, while avibactam protects aztreonam from other β-lactamases 1
• Clinical outcomes: 30-day mortality 19.2% versus 44% with other agents (HR 0.37,95% CI 0.13-0.74) for MBL-producing bloodstream infections 1
• Synergy demonstrated: Restores aztreonam susceptibility in 86% of MBL-producing Enterobacterales 5

Clinical Decision Algorithm

Step 1: Identify the pathogen

• If Pseudomonas aeruginosa → Prefer ceftolozane-tazobactam 2
• If Enterobacterales (CRE) → Proceed to Step 2

Step 2: Determine carbapenemase type (whenever possible)

• KPC or OXA-48 producer → Use ceftazidime-avibactam alone 1
• MBL producer (NDM, VIM) → Use ceftazidime-avibactam PLUS aztreonam 1
• Unknown carbapenemase → If high suspicion for MBL (geographic prevalence, prior testing), use combination therapy 1

Step 3: Consider infection severity and site

• For severe infections with susceptible organisms on either agent: monotherapy is appropriate; do NOT add combination therapy 2
• For non-severe infections: Consider older agents if active in vitro for stewardship purposes 2

Critical Pitfalls to Avoid

1. Do NOT use ceftazidime-avibactam alone for MBL producers – it will fail clinically despite potential in vitro activity of the cephalosporin component 1

2. Do NOT add combination therapy to CAZ-AVI or C-T when treating susceptible organisms – strong recommendation against this practice 2

3. Ascertain carbapenemase type before treatment initiation whenever feasible through molecular testing or prior culture data 1

4. For recurrent Pseudomonas infections, ceftolozane-tazobactam may offer advantage over ceftazidime-avibactam (moderate certainty evidence) 3

Safety Considerations

• Ceftazidime-avibactam: Lower acute kidney injury risk (RR 0.37,95% CI 0.16-0.83) compared to older agents 1
• Both agents: Generally well-tolerated with low adverse event rates 4, 6
• Combination therapy (CAZ-AVI + ATM): No significant increase in adverse events compared to monotherapy, overall mortality 21% in treated populations 1

Pharmacokinetic Considerations

When administering CAZ-AVI plus aztreonam separately, ensure synchronized dosing to maintain adequate inhibitor exposure throughout aztreonam's dosing interval 7. The fixed-dose combination aztreonam-avibactam (when available) eliminates this concern but is not yet widely accessible 7.